Chiasma Inc (NASDAQ:CHMA) has been given a consensus rating of “Buy” by the six analysts that are currently covering the stock, MarketBeat.com reports. One analyst has rated the stock with a hold recommendation and five have issued a buy recommendation on the company. The average 12-month price target among analysts that have issued ratings on the stock in the last year is $15.00.
Several equities research analysts recently weighed in on the stock. Cantor Fitzgerald set a $18.00 price target on shares of Chiasma and gave the company a “buy” rating in a research report on Friday, June 28th. HC Wainwright downgraded shares of Hydrogenics from a “buy” rating to a “neutral” rating in a research report on Friday, June 28th. Finally, Zacks Investment Research downgraded shares of ExlService from a “hold” rating to a “sell” rating in a research report on Wednesday.
Shares of CHMA stock traded down $0.27 during trading hours on Friday, hitting $6.33. 5,060 shares of the company’s stock traded hands, compared to its average volume of 394,230. The stock has a fifty day moving average price of $7.40. Chiasma has a 12-month low of $1.20 and a 12-month high of $8.29. The firm has a market cap of $204.28 million, a PE ratio of -4.91 and a beta of 1.20.
Chiasma (NASDAQ:CHMA) last announced its quarterly earnings results on Thursday, May 9th. The biotechnology company reported ($0.36) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.34) by ($0.02). Equities analysts predict that Chiasma will post -1.14 earnings per share for the current year.
In related news, Director Roni Mamluk sold 10,000 shares of the firm’s stock in a transaction that occurred on Tuesday, April 16th. The shares were sold at an average price of $5.31, for a total transaction of $53,100.00. Following the completion of the sale, the director now owns 10,000 shares of the company’s stock, valued at $53,100. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 6.20% of the stock is owned by company insiders.
A number of large investors have recently bought and sold shares of CHMA. Millennium Management LLC purchased a new position in shares of Chiasma during the 4th quarter worth $41,000. Acadian Asset Management LLC boosted its stake in shares of Chiasma by 99.1% during the 4th quarter. Acadian Asset Management LLC now owns 22,647 shares of the biotechnology company’s stock worth $70,000 after acquiring an additional 11,273 shares during the last quarter. Tibra Equities Europe Ltd purchased a new position in shares of Chiasma during the 1st quarter worth $200,000. Deutsche Bank AG boosted its stake in shares of Chiasma by 27.8% during the 4th quarter. Deutsche Bank AG now owns 78,198 shares of the biotechnology company’s stock worth $243,000 after acquiring an additional 16,996 shares during the last quarter. Finally, Dimensional Fund Advisors LP boosted its stake in shares of Chiasma by 20.6% during the 4th quarter. Dimensional Fund Advisors LP now owns 97,644 shares of the biotechnology company’s stock worth $304,000 after acquiring an additional 16,658 shares during the last quarter. 62.78% of the stock is owned by institutional investors and hedge funds.
Chiasma, Inc, a clinical-stage biopharmaceutical company, focuses on developing oral medications using transient permeability enhancer technology platform for the treatment of rare and serious chronic disease in the United States, Europe, and internationally. The company offers oral octreotide capsules for adult patients under the MYCAPSSA name, which is in two Phase III clinical trials for the treatment of acromegaly, a condition that results in the body's production of excess growth hormone.
Featured Story: How is the Producer Price Index calculated?
Receive News & Ratings for Chiasma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chiasma and related companies with MarketBeat.com's FREE daily email newsletter.